None listed
Conditions
Brief summary
Most cervical cell abnormalities are caused by infection with high risk types of human papillomavirus (HPV). In 2008, a national HPV vaccination programme was commenced in New Zealand. The vaccine protects women from infection with HPV 16 and 18, the HPV types associated with the majority of cervical cell abnormalities (precancers) and cervical cancer. A previous study found that at that time (2009-2011), approximately 70% of women aged under 29 with high grade cervical cell abnormalities were infected with HPV 16 or 18. Our study aims to determine the HPV types carried by young women (aged 20-24 years) with abnormal cervical cells in New Zealand currently and to compare this with previous data. We hypothesize that young women with high grade disease will have HPV 16 or 18 in the minority of cases and that in both vaccinated and non-vaccinated women this will be less than that seen in the historical study.
Interventions
All women aged 20-24 years attending colposcopy following abnormal screening cytology in participating centres will be invited to participate in the study. Consenting women will have a cytology sample taken from the cervix as part of their colposcopy. High risk HPV testing and extended genotyping will be performed by the BD viper assay performed by Canterbury Health Laboratory or partial genotyping (HPV 16, HPV 18, other high risk HPV, or high risk HPV not detected) using the HPV assay routine
All women aged 20-24 years attending colposcopy following abnormal screening cytology in participating centres will be invited to participate in the study. Consenting women will have a cytology sample taken from the cervix as part of their colposcopy. High risk HPV testing and extended genotyping will be performed by the BD viper assay performed by Canterbury Health Laboratory or partial genotyping (HPV 16, HPV 18, other high risk HPV, or high risk HPV not detected) using the HPV assay routinely used by that laboratory. This will be a one-off test and there will be no further follow-up specific to the study.
Sponsors
University of Otago, Christchurch
Eligibility
Sex/Gender
All
Age
20 Years to 24 Years
Healthy volunteers
No
Inclusion criteria
Women aged 20-24 years. Referred to colposcopy (at a participating centre) with an abnormal smear.
Exclusion criteria
None
Outcome results
None listed